| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
SI-2 HCl targets steroid receptor coactivator 3 (SRC-3), a transcriptional coactivator frequently overexpressed in cancers, including breast cancer. SRC-3 is a member of the p160 family of coactivators that enhance the transcriptional activity of nuclear receptors and other transcription factors. By blocking SRC-3 activity, SI-2 HCl inhibits the growth of SRC-3-dependent cancer cells. It also reduces SRC1 and SRC2 levels.
|
|---|---|
| ln Vitro |
Through a direct physical response to SRC-3, SI-2 hydrochloride specifically decreases the protein concentration and regulatory function of intracellular SRC-3 [1]. SI-2 hydrochloride has IC50 values in the low nanomolar range and specifically promotes apoptosis of breast cancer cells. MDAMB-468 cell motility, proliferation, and tumor metastasis are all decreased by SI-2 hydrochloride (100 nM) [1]. Determination of cell viability [1]. (3–20 nM), yet it has no effect on regular cell viability[1].
SI-2 HCl exhibits potent in vitro activity as an SRC-3 inhibitor. It induces breast cancer cell death with IC50 values of 3-20 nM. It reduces SRC1, SRC2, and SRC3 levels in breast cancer cell lines and inhibits cell growth with an IC50 of 3.4 nM. It induces apoptosis. These in vitro activities confirm its potential as an anticancer agent. |
| ln Vivo |
SI-2 hydrochloride exhibits negligible chronic toxicity to major organs based on histological study and minimal acute cardiac toxicity according to the hERG channel blocking test [1]. One kind of drug molecule that meets all of Lipinski's requirements is SI-2 hydrochloride. [1]
In vivo, SI-2 HCl significantly inhibits breast tumor growth. It has favorable pharmacokinetic properties and improved toxicity, with acceptable oral availability. These properties make it suitable for in vivo studies and support its potential as a therapeutic agent for breast cancer. |
| Enzyme Assay |
In vitro receptor binding assays for SI-2 HCl involve measuring its inhibition of SRC-3 coactivator function. These assays typically use a cell-based reporter system where SRC-3 enhances the transcriptional activity of a nuclear receptor (e.g., estrogen receptor). The compound is added to the cells, and the reduction in reporter gene activity is measured. SRC-3 protein levels are measured by Western blot.
|
| Cell Assay |
Cell viability determination[1]. (3 -20 nM), but does not affect normal cell viability[1].
Cell Types: MDA-MB-468 cells. Tested Concentrations: 100 nM. Incubation Duration: 12 hrs (hours). Experimental Results: Significant reduction in cancer cell motility. Western Blot Analysis[1]. Cell Types: MDAMB-468 cells. Tested Concentrations: 0-200 nM. Incubation Duration: 24 hrs (hours). Experimental Results: SRC-3 protein levels were Dramatically diminished. SRC-3 mRNA levels were not diminished. Western Blot Analysis[1]. Cell Types: cancer cells. Tested Concentrations: 0-200 nM. Incubation Duration: 24 hrs (hours). Experimental Results: Causes PARP cleavage. In vitro cellular assays for SI-2 HCl are conducted in breast cancer cell lines. Cells are treated with the compound at various concentrations, and cell proliferation is measured using MTT or CellTiter-Glo assays. Apoptosis is assessed by Annexin V staining, caspase activity assays, or PARP cleavage. SRC-3 target gene expression is measured by qPCR. These assays characterize the compound's anticancer activity. |
| Animal Protocol |
Animal/Disease Models: MDA-MB-468 breast cancer mouse model [1].
Doses: 2 mg/kg. Dosing: twice (two times) daily for 5 weeks (vehicle, PBS). Experimental Results: Dramatically inhibited tumor growth. SRC-3 levels in SI-2-treated tumor tissues were Dramatically lower than those in PBS-treated controls. Animal/Disease Models: CD1 mouse[1]. Doses: 20 mg/kg (pharmacokinetic/PK/PK analysis). Route of Administration: Administer intraperitoneally (ip) (ip) once. Experimental Results: T1/2=1 hour, Cmax is 3.0μM, and the time to reach the maximum plasma concentration tmax is 0.25 hrs (hrs (hours)). SI-2 degrades only slightly (less than 5%) within 6 hrs (hrs (hours)) at pH 1.6 and 3.0 and is stable in buffers at pH ≥ 5. In vivo animal experiments with SI-2 HCl are conducted in mouse xenograft models of breast cancer. Tumor-bearing mice are administered SI-2 HCl orally or by injection at various doses. Tumor growth is monitored, and tumor tissues are harvested for analysis of SRC-3 levels, apoptosis markers, and cell proliferation. Pharmacodynamic studies are performed to confirm target engagement. |
| ADME/Pharmacokinetics |
SI-2 HCl is an orally available compound with favorable pharmacokinetic properties. It has a molecular weight of 301.77 and a molecular formula of C15H16ClN5. The compound is soluble in DMSO and is typically stored at -20°C. Its half-life, bioavailability, and tissue distribution have been characterized in preclinical studies.
|
| Toxicity/Toxicokinetics |
SI-2 HCl has been evaluated for safety in preclinical studies. It has improved toxicity compared to other SRC-3 inhibitors. The compound is intended for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Song X, et al. Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc Natl Acad Sci U S A. 2016 May 3;113(18):4970-5.
|
| Additional Infomation |
SI-2 HCl (EPH 116 hydrochloride) is a potent inhibitor of steroid receptor coactivator 3 (SRC-3). It induces breast cancer cell death with IC50 values of 3-20 nM and significantly inhibits breast tumor growth in vivo. It has favorable pharmacokinetic properties and improved toxicity. It reduces SRC1, SRC2, and SRC3 levels in breast cancer cell lines.
|
| Molecular Formula |
C15H16CLN5
|
|---|---|
| Molecular Weight |
301.774041175842
|
| Exact Mass |
301.109
|
| CAS # |
1992052-49-9
|
| PubChem CID |
121513909
|
| Appearance |
Pink to red solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
356
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C/C(=N/NC1=NC2=CC=CC=C2N1C)/C3=CC=CC=N3.Cl
|
| InChi Key |
CDYJHORKRVKALB-VVTVMFAVSA-N
|
| InChi Code |
InChI=1S/C15H15N5.ClH/c1-11(12-7-5-6-10-16-12)18-19-15-17-13-8-3-4-9-14(13)20(15)2;/h3-10H,1-2H3,(H,17,19);1H/b18-11-;
|
| Chemical Name |
1-methyl-N-[(Z)-1-pyridin-2-ylethylideneamino]benzimidazol-2-amine;hydrochloride
|
| Synonyms |
SI2 HCl; SI 2 HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~16.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3138 mL | 16.5689 mL | 33.1378 mL | |
| 5 mM | 0.6628 mL | 3.3138 mL | 6.6276 mL | |
| 10 mM | 0.3314 mL | 1.6569 mL | 3.3138 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
